News

Published on 6 Aug 2023 on Simply Wall St. via Yahoo Finance

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be


Article preview image

The latest analyst coverage could presage a bad day for uniQure N.V. (NASDAQ:QURE), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon.

Following the latest downgrade, the current consensus, from the 16 analysts covering uniQure, is for revenues of US$107m in 2023, which would reflect a perceptible 4.1% reduction in uniQure's sales over the past 12 months. Per-share losses are expected to see a sharp uptick, reaching US$4.34. However, before this estimates update, the consensus had been expecting revenues of US$238m and US$1.29 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.

Check out our latest analysis for uniQure

NASDAQ.QURE price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday’s...

Shares of Butterfly Network, Inc. BFLY fell sharply during Thursday’s session after the company...

Benzinga 29 Feb 2024

12 Best Medical Stocks to Buy Under $10

In this article, we will take a look at the 12 best medical stocks to buy under $10. To skip our ...

Insider Monkey via Yahoo Finance 27 Feb 2024

12 Best Genomics Stocks To Buy Now

In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip...

Insider Monkey via Yahoo Finance 10 Dec 2023

Shareholders in uniQure (NASDAQ:QURE) are in the red if they invested three years ago

uniQure N.V. (NASDAQ:QURE) shareholders should be happy to see the share price up 24% in the last...

Simply Wall St. via Yahoo Finance 2 Dec 2023

Calculating The Fair Value Of uniQure N.V. (NASDAQ:QURE)

Key Insights The projected fair value for uniQure is US$7.03 based on 2 Stage Free Cash Flow to E...

Simply Wall St. via Yahoo Finance 11 Nov 2023

Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback

It was a busy week for the biotech sector. M&A is back in the spotlight in the sector as Bristol ...

Zacks via Yahoo Finance 12 Oct 2023

uniQure (QURE) Up on Restructuring Plans, Workforce Reduction

Shares of uniQure N.V. QURE were up 11.61% on Oct 5 after the company announced a strategic reorg...

Zacks via Yahoo Finance 6 Oct 2023

In the wake of uniQure N.V.'s (NASDAQ:QURE) latest US$36m market cap drop, institutional owners may...

Key Insights Institutions' substantial holdings in uniQure implies that they have significant inf...

Simply Wall St. via Yahoo Finance 5 Oct 2023

Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be

The latest analyst coverage could presage a bad day for uniQure N.V. (NASDAQ:QURE), with the anal...

Simply Wall St. via Yahoo Finance 6 Aug 2023

uniQure (QURE) Falls on Mixed Huntington's Disease Study Results

uniQure Inc. QURE announced interim results from its ongoing phase I/II study of AMT-130 for the ...

Zacks via Yahoo Finance 22 Jun 2023